glp 1 med names GLP-1 medications are not approved by the Food and Drug Administration to treat polyendocrine metabolic ovarian syndrome (PMOS), the condition renamed from polycystic ovary syndrome in 2026. Because the use is off-label List of approved and pending

Sanaya, N., Janusaite, M., Dalamaga, M

The signs that matter clinically are carpal-tunnel-like wrist symptoms, persistent joint pain, or elevated blood glucose, these usually indicate IGF-1 is too high and dosing needs to be reduced

Purity: 98% (HPLC tested)

Two quick release softgels per day deliver 500 mg of reduced L-Glutathione, which offers optimal absorption

The drugs lack of efficacy in this context does not preclude its potential utility in the broader, more heterogeneous population of older adults experiencing cognitive decline, where vascular and metabolic factors frequently play a major role

However, these tolerability issues ultimately impeded its regulatory and clinical progression